RBP4 and Insulin resistance: For example, a recent randomized and double-blind trial demonstrated that the DPPIV inhibitor sitagliptin attenuated insulin resistance and improved overall glycaemic control in women with GDM by a purported reduction in RBP4 (Retinol Binding Protein 4) levels [35].